SG11201407682TA - Heteroaryl-ketone fused azadecalin glucocorticoid receptor modulators - Google Patents

Heteroaryl-ketone fused azadecalin glucocorticoid receptor modulators

Info

Publication number
SG11201407682TA
SG11201407682TA SG11201407682TA SG11201407682TA SG11201407682TA SG 11201407682T A SG11201407682T A SG 11201407682TA SG 11201407682T A SG11201407682T A SG 11201407682TA SG 11201407682T A SG11201407682T A SG 11201407682TA SG 11201407682T A SG11201407682T A SG 11201407682TA
Authority
SG
Singapore
Prior art keywords
gb
international
heteroaryl
receptor modulators
glucocorticoid receptor
Prior art date
Application number
SG11201407682TA
Inventor
Hazel Hunt
Tony Johnson
Nicholas Ray
Iain Walters
Original Assignee
Corcept Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to US201261651669P priority Critical
Priority to US201261691083P priority
Priority to US201261715907P priority
Priority to US201361759520P priority
Priority to US201361781629P priority
Application filed by Corcept Therapeutics Inc filed Critical Corcept Therapeutics Inc
Priority to PCT/US2013/042732 priority patent/WO2013177559A2/en
Publication of SG11201407682TA publication Critical patent/SG11201407682TA/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47Quinolines; Isoquinolines
    • A61K31/472Non-condensed isoquinolines, e.g. papaverine
    • A61K31/4725Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965Non-condensed pyrazines
    • A61K31/497Non-condensed pyrazines containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • A61K31/535Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/53751,4-Oxazines, e.g. morpholine
    • A61K31/53771,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • A61K31/535Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/53751,4-Oxazines, e.g. morpholine
    • A61K31/53831,4-Oxazines, e.g. morpholine ortho- or peri-condensed with heterocyclic ring systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D498/00Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04Ortho-condensed systems

Abstract

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (43) International Publication Date 28 November 2013 (28.11.2013) WIPOIPCT (10) International Publication Number WO 2013/177559 A2 (51) International Patent Classification: A61K 31/5377 (2006.01) C07D 471/02 (2006.01) (21) International Application Number: (22) International Filing Date: (25) Filing Language: (26) Publication Language: PCT/US2013/042732 24 May 2013 (24.05.2013) English English (30) Priority Data: 61/651,669 61/691,083 61/715,907 61/759,520 61/781,629 25 May 2012 (25.05.2012) US 20 August 2012 (20.08.2012) US 19 October 2012 (19.10.2012) US 1 February 2013 (01.02.2013) US 14 March 2013 (14.03.2013) US (71) Applicant: CORCEPT THERAPEUTICS, INC. [US/US]; 149 Commonwealth Drive, Menlo Park, CA 94025 (US). (72) Inventors: HUNT, Hazel; Edenderry House, Bracken Close, Storrington West Sussex (GB). JOHNSON, Tony; Published: 8/9 Spire Green Centre, Flex Meadow, Harlow Essex (GB). RAY, Nicholas; 8/9 Spire Green Centre, Flex Meadow, Harlow Essex (GB). WALTERS, Iain; BioCity, Pennyfoot Street, Nottingham NG1 IGF (GB). (74) Agents: TRIMBLE, Alexander, R. et al.; Kilpatrick Townsend & Stockton, LLP, Two Embarcadero Center, Eighth Floor, San Francisco, CA 94111 (US). (81) Designated States (unless otherwise indicated, for every kind of national protection available)'. AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (84) Designated States (unless otherwise indicated, for every kind of regional protection available)'. ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG). — without international search report and to be republished upon receipt of that report (Rule 48.2(g)) CJ as i> i> i-H o CJ (54) Title: HETEROARYL-KETONE FUSED AZADECALIN GLUCOCORTICOID RECEPTOR MODULATORS (57) Abstract: The present invention provides heteroaryl ketone fused azadecalin compounds and methods of using the compounds as glucocorticoid receptor modulators.
SG11201407682TA 2012-05-25 2013-05-24 Heteroaryl-ketone fused azadecalin glucocorticoid receptor modulators SG11201407682TA (en)

Priority Applications (6)

Application Number Priority Date Filing Date Title
US201261651669P true 2012-05-25 2012-05-25
US201261691083P true 2012-08-20 2012-08-20
US201261715907P true 2012-10-19 2012-10-19
US201361759520P true 2013-02-01 2013-02-01
US201361781629P true 2013-03-14 2013-03-14
PCT/US2013/042732 WO2013177559A2 (en) 2012-05-25 2013-05-24 Heteroaryl-ketone fused azadecalin glucocorticoid receptor modulators

Publications (1)

Publication Number Publication Date
SG11201407682TA true SG11201407682TA (en) 2014-12-30

Family

ID=49624542

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11201407682TA SG11201407682TA (en) 2012-05-25 2013-05-24 Heteroaryl-ketone fused azadecalin glucocorticoid receptor modulators

Country Status (20)

Country Link
EP (3) EP2854814B1 (en)
JP (1) JP6172871B2 (en)
CN (1) CN104619328B (en)
AU (1) AU2013266110C1 (en)
CA (1) CA2872260A1 (en)
CL (1) CL2014003173A1 (en)
DK (2) DK2854814T3 (en)
ES (1) ES2665338T3 (en)
HK (1) HK1208818A1 (en)
IL (1) IL235868A (en)
MX (1) MX365423B (en)
NZ (1) NZ701469A (en)
PE (1) PE20150352A1 (en)
PH (1) PH12014502584A1 (en)
PL (1) PL2854814T3 (en)
PT (1) PT2854814T (en)
RU (1) RU2639867C2 (en)
SG (1) SG11201407682TA (en)
WO (1) WO2013177559A2 (en)
ZA (1) ZA201408182B (en)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8859774B2 (en) 2012-05-25 2014-10-14 Corcept Therapeutics, Inc. Heteroaryl-ketone fused azadecalin glucocorticoid receptor modulators
CN106029066B (en) * 2013-11-25 2019-03-15 科赛普特治疗公司 The condensed Azadecalin glucocorticoid receptor modulators of octahydro
EP3265127A4 (en) * 2015-03-02 2018-08-15 Corcept Therapeutics, Inc. Use of glucocorticoid receptor antagonist and somatostatin analogues to treat acth-secreting tumors
US20180291451A1 (en) * 2015-05-18 2018-10-11 Corcept Therapeutics, Inc. Methods for diagnosing and assessing treatment for cushing's syndrome
KR20180052120A (en) * 2015-08-13 2018-05-17 코어셉트 쎄라퓨틱스, 잉크. Differential diagnosis of ACTH-dependent Cushing's syndrome
WO2017151613A1 (en) * 2016-03-01 2017-09-08 Corcept Therapeutics, Inc. The use of glucocorticoid receptor modulators to potentiate checkpoint inhibitors
US9943505B2 (en) 2016-09-09 2018-04-17 Corcept Therapeutics, Inc. Glucocorticoid receptor modulators to treat pancreatic cancer

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4391904A (en) 1979-12-26 1983-07-05 Syva Company Test strip kits in immunoassays and compositions therein
GB8828669D0 (en) * 1988-12-08 1989-01-11 Lilly Industries Ltd Organic compounds
JP4931794B2 (en) * 2004-03-09 2012-05-16 コーセプト セラピューティクス, インコーポレイテッド Fused ring azadecalin glucocorticoid receptor modulators
US7640389B2 (en) * 2006-02-28 2009-12-29 Freescale Semiconductor, Inc. Non-volatile memory having a multiple block erase mode and method therefor
EP1932843A1 (en) * 2006-12-14 2008-06-18 sanofi-aventis Sulfonyl-phenyl-2H-(1,2,4) oxadiazole-5-one derivatives, processes for their preparation and their use as pharmaceuticals
MX2013002186A (en) * 2010-08-27 2013-06-28 Corcept Therapeutics Inc Pyridyl-amine fused azadecalin modulators.

Also Published As

Publication number Publication date
EP3590517A1 (en) 2020-01-08
AU2013266110B2 (en) 2017-04-20
MX2014014239A (en) 2015-08-05
CA2872260A1 (en) 2013-11-28
ZA201408182B (en) 2017-09-27
DK3338781T3 (en) 2019-12-09
IL235868A (en) 2017-12-31
DK2854814T3 (en) 2018-03-12
PH12014502584B1 (en) 2015-01-21
RU2014152625A (en) 2016-07-20
MX365423B (en) 2019-06-03
AU2013266110C1 (en) 2018-07-12
PT2854814T (en) 2018-03-15
WO2013177559A2 (en) 2013-11-28
EP2854814B1 (en) 2018-01-31
RU2639867C2 (en) 2017-12-25
AU2013266110A1 (en) 2014-11-20
PH12014502584A1 (en) 2015-01-21
CN104619328A (en) 2015-05-13
EP2854814A4 (en) 2016-01-27
KR20150021955A (en) 2015-03-03
CN104619328B (en) 2018-10-02
CL2014003173A1 (en) 2015-02-27
PL2854814T3 (en) 2018-07-31
JP2015517580A (en) 2015-06-22
HK1208818A1 (en) 2016-03-18
EP2854814A2 (en) 2015-04-08
NZ701469A (en) 2017-06-30
WO2013177559A3 (en) 2014-01-16
EP3338781A1 (en) 2018-06-27
JP6172871B2 (en) 2017-08-02
IL235868D0 (en) 2015-01-29
PE20150352A1 (en) 2015-03-16
ES2665338T3 (en) 2018-04-25
EP3338781B1 (en) 2019-09-11

Similar Documents

Publication Publication Date Title
AU2015213334C1 (en) Methods for increasing tolerance to abiotic stress in plants
SG11201407674TA (en) D-amino acid compounds for liver disease
SG11201408067YA (en) Crystalline forms of a bruton's tyrosine kinase inhibitor
SG11201408324QA (en) Pyridinone and pyridazinone derivatives
SG11201403402VA (en) Compounds
SG11201407970VA (en) Modulation of hepatitis b virus cccdna transcription
SG11201408045UA (en) MACROCYCLIC INHIBITORS OF <i>FLAVIVIRIDAE</i> VIRUSES
SG11201408047XA (en) Macrocyclic inhibitors of flaviviridae viruses
SG11201408279QA (en) Social sharing of security information in a group
SG11201408013WA (en) Solid forms of an antiviral compound
SG11201408124PA (en) Differentiation of human embryonic stem cells into pancreatic endocrine cells
SG11201406943XA (en) Activatable antibodies that bind epidermal growth factor receptor and methods of use thereof
SG11201407268SA (en) Nuclear transport modulators and uses thereof
SG11201804161VA (en) Compositions comprising bacterial strains
SG11201808708RA (en) Heterocyclic amides useful as protein modulators
SG11201408385TA (en) Methods of detecting diseases or conditions
SG11201408095XA (en) Fibroblast growth factor 21 proteins
SG11201407017WA (en) Site-specific labeling methods and molecules produced thereby
SG11201407819UA (en) Improved methods of cell culture for adoptive cell therapy
SG11201811414TA (en) Heterocyclic compounds as immunomodulators
SG11201408821SA (en) Selective pi3k delta inhibitors
SG11201407472SA (en) Motion compensation and motion estimation leveraging a continuous coordinate system
SG11201407486PA (en) Compositions and methods for modulating utrn expression
SG11201804118VA (en) Compositions comprising bacterial strains
SG11201808621TA (en) Heterocyclic amides useful as protein modulators